<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888910</url>
  </required_header>
  <id_info>
    <org_study_id>NIMISA</org_study_id>
    <nct_id>NCT04888910</nct_id>
  </id_info>
  <brief_title>Novel Inflammatory Markers in Different Phenotypes of Severe Asthma</brief_title>
  <official_title>Novel Inflammatory Markers in Different Phenotypes of Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a highly prevalent chronic airway inflammatory disease characterized by airway&#xD;
      hyper-responsiveness, reversible airflow obstruction and increased mucus secretion, involving&#xD;
      large and small airways. An emerging sub-phenotype of severe asthma is the late onset disease&#xD;
      associated with nasal polyposis, a frequent co-morbidity that significantly impacts lung&#xD;
      function and symptom control. On the basis of the infiltrate found in the sputum, asthma can&#xD;
      be divided into four distinct phenotypes: eosinophilic, neutrophilic, mixed granulocytic and&#xD;
      pauci-granulocytic. The majority of patients with eosinophilic asthma are sensitive to&#xD;
      corticosteroids, and biological therapies targeting eosinophils (anti-Interleukin (IL)-5 and&#xD;
      anti-IL5R) have been recently approved. However, it is known that some asthmatics,&#xD;
      particularly those who have severe disease and are resistant to corticosteroids, have&#xD;
      elevated neutrophil counts in the airway where they play a vital role in the exacerbation of&#xD;
      the disease. However, the precise role of neutrophils in severe asthma and the mechanisms&#xD;
      involved in neutrophil-induced tissue damage have not been clarified yet.&#xD;
&#xD;
      The hypothesis of the study is that neutrophils and eosinophils can contribute to the&#xD;
      severity of asthma by changing their phenotypes according to the airway environment. Thus, a&#xD;
      better understanding of the roles of neutrophils and eosinophils in severe asthma may lead to&#xD;
      the identification of novel biomarkers and the development of new therapeutic approaches in&#xD;
      different phenotypes of severe asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cell receptors</measure>
    <time_frame>2 years</time_frame>
    <description>to identify neutrophil- and eosinophil-receptors in the airways of severe asthmatic patients with or without involvement of the upper airways</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cell mediators</measure>
    <time_frame>2 years</time_frame>
    <description>to identify soluble and matrix-derived mediators from neutrophils and eosinophils in the airways of severe asthmatic patients with or without involvement of the upper airways</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Asthma</condition>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>asthma with nasal polyps</arm_group_label>
    <description>severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe asthma without nasal polyps</arm_group_label>
    <description>severe asthma without involvement of the upper airways</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>observation of biomarkers in different asthma groups</description>
    <arm_group_label>asthma with nasal polyps</arm_group_label>
    <arm_group_label>severe asthma without nasal polyps</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        severe asthmatic patients referred to the asthma clinic with or without upper airways&#xD;
        involvement. Some of them are currently under biological therapies according to their grade&#xD;
        of disease in addition to inhaled therapies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  age (18-65 years)&#xD;
&#xD;
          -  Diagnosis of severe asthma according to the European Respiratory Society (ERS) and&#xD;
             American Thoracic Society (ATS) definition, with and without nasal symptoms&#xD;
&#xD;
          -  normal pulmonary function post-therapy (FEV1 post-bronchodilation: greater than 80% of&#xD;
             the predicted value, with FEV1/ vital capacity (VC) &gt; 88-89% - for males and females,&#xD;
             respectively - of the predicted value)&#xD;
&#xD;
          -  non reversible chronic airflow limitation (FEV1 post-bronchodilation: lower than 70%&#xD;
             of the predicted value, with FEV1/VC &lt; 88-89% of the predicted value)&#xD;
&#xD;
          -  Signing of the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Referred Pregnancy&#xD;
&#xD;
          -  Use of therapy with beta-blockers&#xD;
&#xD;
          -  Smoking (current or within the previous 3 months)&#xD;
&#xD;
          -  Negation to participate to the study&#xD;
&#xD;
          -  Current upper and lower airways infectious diseases&#xD;
&#xD;
          -  Current systemic infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilaria Puxeddu, MD, PhD</last_name>
    <phone>+393394740912</phone>
    <email>ilaria.puxeddu@unipi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pisa University</name>
      <address>
        <city>Pisa</city>
        <state>Tuscany</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Puxeddu, MD, PhD</last_name>
      <phone>+393394740912</phone>
      <email>ilaria.puxeddu@unipi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Wu W, Bleecker E, Moore W, Busse WW, Castro M, Chung KF, Calhoun WJ, Erzurum S, Gaston B, Israel E, Curran-Everett D, Wenzel SE. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014 May;133(5):1280-8. doi: 10.1016/j.jaci.2013.11.042. Epub 2014 Feb 28.</citation>
    <PMID>24589344</PMID>
  </results_reference>
  <results_reference>
    <citation>Wenzel SE, Jayawardena S, Graham NM, Pirozzi G, Teper A. Severe asthma and asthma-chronic obstructive pulmonary disease syndrome - Authors' reply. Lancet. 2016 Dec 3;388(10061):2742. doi: 10.1016/S0140-6736(16)31720-2. Epub 2016 Dec 2.</citation>
    <PMID>27924776</PMID>
  </results_reference>
  <results_reference>
    <citation>Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol. 2017 Dec;38(12):942-954. doi: 10.1016/j.it.2017.07.003. Epub 2017 Aug 4. Review.</citation>
    <PMID>28784414</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Ilaria Puxeddu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>eosinophils</keyword>
  <keyword>neutrophils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

